0001209191-22-051632.txt : 20220930
0001209191-22-051632.hdr.sgml : 20220930
20220930161551
ACCESSION NUMBER: 0001209191-22-051632
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220928
FILED AS OF DATE: 20220930
DATE AS OF CHANGE: 20220930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heery Christopher
CENTRAL INDEX KEY: 0001789632
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41259
FILM NUMBER: 221284232
MAIL ADDRESS:
STREET 1: C/O PRECISION BIOSCIENCES, INC.
STREET 2: 302 E. PETTIGREW STREET, SUITE A-100
CITY: DURHAM
STATE: NC
ZIP: 27701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcellx, Inc.
CENTRAL INDEX KEY: 0001786205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472855917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25 WEST WATKINS MILL ROAD
STREET 2: SUITE A
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-723-6641
MAIL ADDRESS:
STREET 1: 25 WEST WATKINS MILL ROAD
STREET 2: SUITE A
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-28
0
0001786205
Arcellx, Inc.
ACLX
0001789632
Heery Christopher
C/O ARCELLX, INC.
25 WEST WATKINS MILL ROAD, SUITE A
GAITHERSBURG
MD
20878
0
1
0
0
Chief Medical Officer
Stock Option (right to buy)
19.97
2022-09-28
4
A
0
40000
0.00
A
2032-09-28
Common Stock
40000
40000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Start Date on the same day of the month as the Vesting Start Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Start Date" shall mean January 1, 2023.
Exhibit 24 - Power of Attorney
/s/ Michelle Gilson, as Attorney-in-Fact
2022-09-30
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Arcellx, Inc. (the
"Company"), hereby constitutes and appoints Rami Elghandour, Michelle Gilson,
Daniel Koeppen and Jennifer Fang the undersigned's true and lawful
attorneys-in-fact to:
1. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorneys-in-fact shall in their discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorneys-in-fact shall deem
appropriate.
The undersigned hereby ratifies and confirms all that said attorneys in-fact and
agent shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 12th day of June 2022.
Signature: /s/ Christopher R. Heery M.D.
Print Name: Christopher R. Heery M.D.